Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II) February 12, 2021
Ensoma Announces Strategic Collaboration with Takeda to Accelerate Next-Generation In Vivo Gene Therapies February 11, 2021
Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First “Off-the-shelf” Genomic Medicines February 11, 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products February 10, 2021
Equip, a startup providing virtual therapy for eating disorders, raises $13 million February 10, 2021
Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH) February 9, 2021
Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma February 8, 2021
Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™ February 5, 2021
Orchard Therapeutics Announces $150 Million Strategic Financing Strengthened Financial Position Supports Execution into the First Half of 2023 February 5, 2021